Wang Jing, Li Yu-Chuan, Deng Min, Jiang Hai-Yin, Guo Li-Hua, Zhou Wen-Juan, Ruan Bing
Department of Cardiology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Oncotarget. 2017 Jul 12;8(46):81098-81108. doi: 10.18632/oncotarget.19186. eCollection 2017 Oct 6.
Previous studies have supported an association between serum insulin-like growth factor-1 (IGF1) and IGF-binding protein 3 (IGFBP3) levels and hepatocellular carcinoma (HCC), but the results were inaccurate. It has recently been proposed that IGF1 and IGFBP3 play roles in the time-to-progression (TTP) and overall survival (OS) of HCC patients. Our results revealed that serum IGF1 level is predictive of the progression and survival of HCC patients.
HCC was associated with a significant reduction in serum IGF-1 and IGFBP-3 levels compared to cirrhosis ( = 0.037). Low serum IGF1 levels were predictive of a shorter TTP (OR, 2.74; 95% confidence interval [CI], 1.92-3.90) and poorer OS (odds ratio [OR], 2.20; 95% CI, 1.81-2.68) in HCC patients. The IGF1/IGFBP3 molar ratio was not significantly associated with the risk of HCC (OR, 1.311; 95% CI, 0.761-2.260).
We conducted a comprehensive literature search in PubMed, EMBASE, and the Cochrane Library. Twenty studies met the inclusion criteria and were subjected to statistical analysis. The geometric mean and standard deviation (SD) of serum IGF1 and IGFBP3 levels in the healthy, cirrhosis, and HCC groups were calculated. Pooled odds ratios (ORs) were calculated using a fixed-effects model to analyse the association of serum IGF1 level with the progression and survival of HCC patients.
Serum IGF1 and IGFBP3 levels were positively associated with the incidence of HCC. Serum IGF1 level is an independent prognostic factor for the progression and survival of HCC patients.
既往研究支持血清胰岛素样生长因子-1（IGF1）和IGF结合蛋白3（IGFBP3）水平与肝细胞癌（HCC）之间存在关联，但结果并不准确。最近有人提出，IGF1和IGFBP3在HCC患者的疾病进展时间（TTP）和总生存期（OS）中发挥作用。我们的结果显示，血清IGF1水平可预测HCC患者的病情进展和生存情况。
与肝硬化患者相比，HCC患者血清IGF-1和IGFBP-3水平显著降低（P = 0.037）。低血清IGF1水平可预测HCC患者的TTP较短（比值比[OR]，2.74；95%置信区间[CI]，1.92 - 3.90）以及OS较差（OR，2.20；95% CI，1.81 - 2.68）。IGF1/IGFBP3摩尔比与HCC风险无显著关联（OR，1.311；95% CI，0.761 - 2.260）。
我们在PubMed、EMBASE和Cochrane图书馆进行了全面的文献检索。20项研究符合纳入标准并进行了统计分析。计算了健康组、肝硬化组和HCC组血清IGF1和IGFBP3水平的几何均值和标准差（SD）。采用固定效应模型计算合并比值比（OR），以分析血清IGF1水平与HCC患者病情进展和生存情况的关联。
血清IGF1和IGFBP3水平与HCC发病率呈正相关。血清IGF1水平是HCC患者病情进展和生存的独立预后因素。
